Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$5.29
+4.8%
$4.07
$2.92
$11.20
$32.91M-1.8845,631 shs54,938 shs
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$2.84
+18.1%
$2.23
$1.46
$4.10
N/A0.1944,443 shs53,769 shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$51.20
+1.0%
$49.40
$32.50
$60.60
$3.16B2.26843,939 shs339,485 shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$7.39
+0.8%
$7.40
$3.34
$16.50
$20.80M1.0933,207 shs527 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
KALA BIO, Inc. stock logo
KALA
KALA BIO
0.00%+14.50%+28.40%+24.76%-22.43%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
0.00%+1.25%+29.45%+41.75%+0.53%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
0.00%-8.06%-0.64%+15.21%+48.41%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
0.00%+0.96%+0.14%+58.72%-17.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.3819 of 5 stars
3.51.00.04.40.00.80.6
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.5416 of 5 stars
0.05.00.04.20.00.81.3
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2.1227 of 5 stars
3.51.00.00.02.52.50.0
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
2.6439 of 5 stars
3.53.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera AG stock logo
BFRA
Biofrontera
0.00
N/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.00
Buy$13.50155.20% Upside
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.00
HoldN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$66.1029.10% Upside
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.00
Buy$40.00441.27% Upside

Current Analyst Ratings Breakdown

Latest MEIP, SLGL, KALA, PTGX, and BFRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$72.00
6/3/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/2/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$15.00
5/23/2025
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/19/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
4/10/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M8.77N/AN/A$2.02 per share2.62
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$65.30MN/A$6.30 per share0.45$4.96 per shareN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M7.30$4.53 per share11.30$11.33 per share4.52
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$11.54M1.79N/AN/A$10.36 per share0.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/17/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.7568.27N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)

Latest MEIP, SLGL, KALA, PTGX, and BFRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/23/2025Q1 2025
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A-$3.20N/A-$3.20N/A$1.03 million
5/13/2025Q3 2025
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A-$0.39N/A-$0.39N/AN/A
5/6/2025Q1 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.19
1.99
1.99
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A
16.78
16.78
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
17.25
17.26
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
5.12
5.12

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
52.38%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
26.18%

Insider Ownership

CompanyInsider Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
N/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
8.32%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
3.12%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
4.90%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
66.51%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
306.45 million5.92 millionNot Optionable
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
100N/AN/AOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12061.98 million58.95 millionOptionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
502.79 million933,000Optionable

Recent News About These Companies

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha
Sol-Gel Technologies Ltd
Sol Gel Tech Stock Price History
Sol-Gel Reports First Quarter 2025 Results
Sol-Gel Announces Reverse Share Split
Sol-Gel, Mayne Pharma enter product purchase agreement
Sol Gel Technologies Ltd (SLGL) Stock Trading Recap
Sol-Gel Technologies Reports Strong Q3 2024 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$5.29 +0.24 (+4.75%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$5.17 -0.12 (-2.34%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

MEI Pharma stock logo

MEI Pharma NASDAQ:MEIP

$2.84 +0.44 (+18.13%)
Closing price 07/3/2025 03:27 PM Eastern
Extended Trading
$2.71 -0.13 (-4.55%)
As of 07/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$51.20 +0.51 (+1.01%)
Closing price 07/3/2025 02:41 PM Eastern
Extended Trading
$51.18 -0.03 (-0.05%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Sol-Gel Technologies stock logo

Sol-Gel Technologies NASDAQ:SLGL

$7.39 +0.06 (+0.82%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.